Sign In  |  Register  |  About Corte Madera  |  Contact Us

Corte Madera, CA
September 01, 2020 10:27am
7-Day Forecast | Traffic

  • Search Hotels in Corte Madera

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.49 -0.23 (-0.47%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
26 27 28 29 30 31 32 33 Next >
FDA Approves Sanofi's Enzyme Therapy For Late-Onset Pompe Disease
The 
Via Benzinga
Exposures Product Safety
Stock Market Rally Hits Highs Amid Strong Earnings, Jobs; Square, GM, Etsy Among Key Movers
The Dow, S&P 500 and Nasdaq amid heavy earnings and a hot jobs report. Square, GM and Etsy were notable movers. 
Via Investor's Business Daily
Topics Stocks
Exposures Fossil Fuels US Equities
Exicure Shares Interim Cavrotolimod Data From Early-Stage Trial In Solid Tumor Patients
Exicure Inc (NASDAQ: XCUR) has reported interim results from Phase 1b/2 trial evaluating cavrotolimod (AST-008) in patients with advanced or metastatic solid... 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Earnings Scheduled For July 29, 2021
Companies Reporting Before The Bell • Smith & Nephew (NYSE:SNN) is projected to report earnings for its second quarter. • Cohen & Co (AMEX:COHN) is... 
Via Benzinga
Sanofi - Regeneron's Libtayo/Chemo Treatment Improves Overall Survival First-Line Lung Cancer
The Phase 3 trial of Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Libtayo in combination with platinum-doublet chemotherapy... 
Via Benzinga
How This Historic FDA Approval Benefits Viatris
Here's what the FDA's approval of Semglee, from Viatris and Biocon, means for the former. 
Via The Motley Fool
Exposures Product Safety
Why Translate Bio Stock Soared Today
The biotech is being bought for $3.2 billion. 
Via The Motley Fool
Mid-Afternoon Market Update: Dow Jumps Over 200 Points; Neuronetics Shares Plunge
Toward the end of trading Tuesday, the Dow traded up 0.64% to 35,059.40 while the NASDAQ rose 0.34% to 14,731.57. The S&P also rose, gaining 0.65% to 4,415.65. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Translate Bio Stock Rockets As Sanofi Jumps Into mRNA Technology With $3.2 Billion Takeover
Sanofi is jumping into the messenger RNA game with the $3.2 billion acquisition of Translate Bio, leading TBIO stock to soar Tuesday. 
Via Investor's Business Daily
Exposures COVID-19
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Sanofi Acquires Translate Bio For $38 Per Share In Cash Or $3.2B
Sanofi has entered into a definitive agreement with Translate Bio for $38.00 per share in cash, which represents a total equity value of $3.2B a fully diluted basis. 
Via Talk Markets
Sanofi Bets Big On mRNA Push With Translate Bio Acquisition For $3.2B: Highlights
A year after paying Translate Bio Inc (NASDAQ: TBIO) a whopping $425 million to develop mRNA vaccines for infectious diseases, including COVID-19, Sanofi... 
Via Benzinga
Exposures COVID-19
Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates
The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly negative verdi... 
Via Benzinga
Sanofi (SNY) Q2 2021 Earnings Call Transcript
SNY earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Sanofi Q2 Performance Benefits From Dupixent, Vaccines; Raises 2021 Profit Forecast
Sanofi SA (NASDAQ: SNY) has raised its 2021 profit forecast after its vaccines and blockbuster eczema treatment Dupixent helped boost second-quarter results. Q2 2021... 
Via Benzinga
Regeneron - Sanofi's Dupixent Improves Itch, Hives In Inflammatory Skin Disease Patients
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) have announced topline results from Phase 3 trial evaluating Dupixent (... 
Via Benzinga
Sanofi's Pompe Disease Enzyme Replacement Therapy Gets EMA's CHMP Backing
The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Sanofi SA's (NASDAQ:... 
Via Benzinga
Sanofi-Regeneron's COPD Drug Fails In Mid-Stage Trial, But Shows Potential Benefit In Subgroup of Former Smokers
Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) started their collaboration in chronic obstructive pulmonary disorder (COPD) to target all... 
Via Benzinga
EMA Starts Rolling Review Of Glaxo - Sanofi COVID-19 Vaccine
EMA's human medicines committee has kicked off a rolling review of a COVID-19 vaccine from Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (... 
Via Benzinga
Exposures COVID-19
Sanofi's Oral Treatment For Sleeping Sickness Gets FDA Approval
The FDA has approved Sanofi SA's (NASDAQ: SNY) fexinidazole as the first all-oral treatment for both stages of the Trypanosoma brucei gambiense form of... 
Via Benzinga
Exposures Product Safety
5 French Stocks To Consider For Bastille Day
Bastille Day is France’s National Day, celebrating the Storming of the Bastille on July 14, 1789, a key turning point in the French Revolution. And while the French concept... 
Via Benzinga
Sanofi, GSK Get Nod For Late-Stage COVID-19 Vaccine Trial In India
Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline Plc (NYSE: GSK) have received approval from the Drug Controller General of India (DCGI) for a late-stage... 
Via Benzinga
Exposures COVID-19
WHO Recommends IL-6 Drugs From Sanofi, Roche For Critically-Ill COVID-19 Patients
The World Health Organization (WHO) has endorsed Interleukin-6 (IL-6) receptor antagonists combined with corticosteroids to treat severe COVID-19 cases. Patients... 
Via Benzinga
Exposures COVID-19
Moderna's COVID-19 Vaccine Produced Neutralizing Titers Against All Variants Tested
Moderna Inc (NASDAQ: MRNA) has announced new results from in vitro neutralization studies of sera from individuals vaccinated with its COVID-19 vaccine. The COVID-... 
Via Benzinga
Exposures COVID-19
Sanofi Invests To Build Internal Capabilities in mRNA
Sanofi SA (NASDAQ: SNY) is working towards its R&D approach around mRNA to accelerate the development and delivery of next-generation vaccines. The company will ... 
Via Benzinga
The Daily Biotech Pulse: Sanofi Bets Big On mRNA Tech, Decision Day For MediWound, DiaMedica Issues Kidney Disease Data Readout
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 28) Alexion Pharmaceuticals,... 
Via Benzinga
Saint Warren
Today the WTI oil price rose further up over 1%. 
Via Talk Markets
< Previous 1 2
...
26 27 28 29 30 31 32 33 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 CorteMadera.com & California Media Partners, LLC. All rights reserved.